芦可替尼相关感染风险的管理综述
该综述总结了芦可替尼对免疫系统的抑制机制及其导致的潜伏感染再激活风险,涉及结核、乙肝病毒和水痘带状疱疹病毒,并针对三种临床场景提出了基于风险的管理算法。
要点
- 芦可替尼通过影响适应性和先天性免疫多条通路产生免疫抑制效应。
- 免疫抑制可能导致结核、乙肝病毒和水痘带状疱疹病毒再激活。
- 目前缺乏专门指南评估和管理芦可替尼相关严重感染风险。
核心结论
- 芦可替尼具有独特的免疫抑制作用,可增加潜伏感染再激活风险,需基于风险进行管理。
研究设计与样本
- 本文为综述,回顾芦可替尼免疫抑制机制的现有知识,并介绍作者对三种临床场景的个人管理方法。
主要发现
- 芦可替尼与免疫系统多条通路发生明确且负面的相互作用,涉及适应性和先天性免疫应答。
- 这些病理生理机制可能促进潜伏感染再激活,如结核、乙肝病毒和水痘带状疱疹病毒。
- 感染事件可能致命或导致显著器官功能损害,影响患者接受异基因移植的资格。
临床怎么用
- 临床需关注芦可替尼治疗患者的潜伏感染再激活风险,参考作者提出的基于风险的算法进行管理。
局限性
- 目前缺乏专门指南帮助评估和管理芦可替尼相关严重感染的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.
引用
- Sant'Antonio E, Bonifacio M, Breccia M, et al. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019. PMID: 31468506. doi:10.1111/bjh.16174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。